Brooklyn, New York, May 17, 2021 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Corona Virus Vaccine Market will grow with a CAGR value of 30.2 percent. With the uncontrollable rising cases of COVID-19 especially in heavily populated countries, the healthcare industry is bound to get aggressively involved in offering top-notch vaccines (for preventive measures) to control the viral transfer, and hence, because of which the market will be growing rapidly from 2021-2026.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on Global Corona Virus Vaccine Market - Forecast to 2026

Key Market Insights

  • Inactivated virus type vaccine will foresee a higher growth rate as compared to other type owing to high demand of this type
  • Based on product type, the monovalent vaccine being the most preferred vaccine type will be having the highest share in the market while the multivalent vaccine type will be growing with the highest CAGR value from 2021 to 2026
  • The adult & geriatric patients have been vaccinated the most during the last year and hence this segment holds the largest share in the corona virus vaccine market
  • Based on technology, the vector-based vaccine will attain the highest market position in terms of revenue growth from 2021 to 2026
  • The government vaccination center will be the largest end-user in terms of both volume and value in the market, based on end-user outlook
  • AstraZeneca PLC, Bharat Biotech International Limited, Johnson & Johnson, Sinovac Biotech Ltd., BioNTech SE, Cadila Healthcare Limited, Shanghai Fosun Pharmaceutical Group Co., Ltd., Moderna, Inc., Serum Institute of India, CureVac AG, CanSino Biologics Inc., Pfizer Inc., Arcturus Therapeutics Holdings Inc., Novavax, Inc., Entos Pharmaceuticals, Sanofi S.A., Symvivo, Glaxo Smith Kline PLC, Daiichi Sankyo Company Ltd., and Astellas Pharma Inc. are the key players in the corona virus vaccine market

Request a Sample Copy of the Report @

Vaccine Type Outlook (Revenue, USD Billion, 2021-2026)

  • Inactivated Virus
  • Protein Subunit
  • Non-replicating Viral Vector
  • RNA Vaccine
  • Others [DNA Vaccine & Repurposed Vaccines]

Product Type Outlook (Revenue, USD Billion, 2021-2026)

  • Multivalent Vaccine
  • Monovalent Vaccine

Technology Outlook (Revenue, USD Billion, 2021-2026)

  • Vector-Based
  • Nucleic Acid-Based
  • Protein-Based
  • Whole Virus

Patient Type Outlook (Revenue, USD Billion, 2021-2026)

  • Adult & Geriatric Patients
  • Pediatric Patients

Clinical Trial Phase Outlook (Revenue, USD Billion, 2021-2026)

  • Phase 1
  • Phase 2
  • Phase 3
  • Market Launched

End-User Outlook (Revenue, USD Billion, 2021-2026)

  • Government Vaccination Centers
  • Hospitals & Clinics
  • E-Pharmacy Channel
  • Research & Development Organizations
  • Others

Regional Outlook (Revenue, USD Billion, 2021-2026)

North America        


  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of APAC

Central & South America

  • Brazil
  • Argentina
  • Rest of CSA

Middle East & Africa

  • Saudi Arabia
  • UAE
  • Rest of MEA

Website: Global Market Estimates


Source link